Prime Medicine, founded in 2019 and based in Cambridge, Massachusetts, develops genetic therapies using a proprietary Prime Editing platform. The company emerged from research at the Broad Institute of MIT and Harvard and focuses on creating one-time curative treatments by correcting the genetic causes of disease.
The Prime Editing platform operates as a search-and-replace mechanism for DNA, enabling precise edits at specific genomic locations without creating double-strand breaks. The technology can theoretically address approximately 90% of known disease-causing mutations across diverse organisms, organs and cell types. Prime Medicine has extended this capability through PASSIGE (Prime Assisted Site Specific Integrase Gene Editing), which allows insertion of gene-sized sequences directly into the genome.
The company maintains a diversified pipeline of investigational therapeutic programs organized across four core focus areas: hematology, immunology and oncology, liver diseases, and lung diseases. This platform-based approach enables Prime Medicine to pursue multiple therapeutic applications from a single underlying technology.
